The Complex Relationship Between Atopic Dermatitis and Allergies (AAN) Non-CME

Price: FREE for members and non-members
Not for CME

Session recorded on June 12, 2024
Speaker: Luz S. Fonacier, MD

Patients with atopic dermatitis have higher rates of allergic diseases than the general population. The converse is also true. Patients with allergies have higher rates of atopic dermatitis. In this webinar, learn how to identify and treat food allergies, environmental allergies, contact allergies and treatment-associated allergies in patients living with atopic dermatitis.

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity learners should be able to:
1.    Describe the related allergic conditions that may impact people living with atopic dermatitis.
2.    Explain the treatment options for atopic dermatitis. 
3.    Discuss the different types of allergies that may affect someone living with atopic dermatitis. 

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
Course expires: 

All identified relevant financial relationships with ineligible companies have been mitigated.

Luz S. Fonacier, MD
Research: Regeneron, AstraZeneca
Advisor: Regeneron
Consultant: Abbie, Lilly, Pfizer

Lynda Mitchell, CEO, Allergy Asthma Network (AAN)
No identified relevant finanical relationships with ineligible companies to disclose

Please login or create an account to take this course.